These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34970782)

  • 21. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
    Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W
    Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
    Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
    Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
    Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
    Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
    Tibullo D; Giallongo C; Romano A; Vicario N; Barbato A; Puglisi F; Parenti R; Amorini AM; Wissam Saab M; Tavazzi B; Mangione R; Brundo MV; Lazzarino G; Palumbo GA; Volti GL; Raimondo FD; Lazzarino G
    Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
    Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
    Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
    Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
    J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
    Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
    Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.
    Marino S; Petrusca DN; Bishop RT; Anderson JL; Sabol HM; Ashby C; Layer JH; Cesarano A; Davé UP; Perna F; Delgado-Calle J; Chirgwin JM; Roodman GD
    Haematologica; 2024 May; 109(5):1501-1513. PubMed ID: 37981834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
    Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
    Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
    Alonso S; Hernandez D; Chang YT; Gocke CB; McCray M; Varadhan R; Matsui WH; Jones RJ; Ghiaur G
    J Clin Invest; 2016 Dec; 126(12):4460-4468. PubMed ID: 27775549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
    Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A
    Redox Biol; 2015; 4():23-33. PubMed ID: 25485927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
    Yin L; Kufe T; Avigan D; Kufe D
    Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
    Lipchick BC; Utley A; Han Z; Moparthy S; Yun DH; Bianchi-Smiraglia A; Wolff DW; Fink E; Liu L; Furdui CM; Lee J; Lee KP; Nikiforov MA
    Blood Adv; 2021 Apr; 5(7):1933-1946. PubMed ID: 33821992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
    Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
    Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.
    Ding K; Jiang W; Jia H; Lei M
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound.
    Łuczkowska K; Sokolowska KE; Taryma-Lesniak O; Pastuszak K; Supernat A; Bybjerg-Grauholm J; Hansen LL; Paczkowska E; Wojdacz TK; Machaliński B
    Sci Rep; 2021 May; 11(1):9846. PubMed ID: 33972578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.
    Thirukkumaran CM; Shi ZQ; Nuovo GJ; Luider J; Kopciuk KA; Dong Y; Mostafa AA; Thakur S; Gratton K; Yang A; Chin AC; Coffey MC; Jimenez-Zepeda VH; Stewart D; Chesi M; Bergsagel PL; Morris D
    Blood Adv; 2019 Mar; 3(5):797-812. PubMed ID: 30850386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.